research Variable Clinical Features of Temporal Triangular Alopecia
This report suggests a possible association between temporal triangular alopecia and sebaceous nevus, and identifies a pinkish background as a new trichoscopic finding for TTA.
Search
forResearch
5 / 1000+ results
research Associations between clinical variables and treatment regimens and hair density and calibre in female androgenetic alopecia patients: a retrospective study of 602 patients
This study reports no new results as it is a letter discussing associations between clinical variables, treatment regimens, and hair density and calibre in female androgenetic alopecia patients.
research Molecular–clinical correlations in a family with variable tissue mitochondrial DNA T8993G mutant load
This study found significant variation in tissue mutant load in individuals with the T8993G mutation, which complicates genetic counseling and may inform genotype-phenotype correlations, especially using hair bulb mtDNA analysis.
research Effect of Procedural-Related Variables on Melanocyte–Keratinocyte Suspension Transplantation in Nonsegmental Stable Vitiligo: A Clinical and Immunocytochemical Study
In this study, different donor and recipient site preparation techniques for melanocyte-keratinocyte suspension were associated with similar repigmentation outcomes in stable vitiligo, but efficacy varied by body site.
research BaldGraphFormer: An Explainable Deep Learning Framework for Early Baldness Prediction by Integrating Swin Transformer, Graph Attention Networks and Clinical Features
In this study, the BaldGraphFormer framework, integrating visual and clinical data, outperformed unimodal baselines in early-stage androgenetic alopecia detection, achieving an F1-score of 97.62% and macro-average AUC of 0.992, suggesting its potential to support dermatological decision-making and early intervention.
Community Join
5 / 1000+ resultscommunity PP405 timeframe ? Could it replace current treatments ?
PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.
community Why is 1 mg the go to prescription of finasteride when it’s only 2 procent points more effective than 0.2 mg?
1 mg of finasteride is commonly prescribed because it is more effective for a larger number of people compared to lower doses, despite only slightly reducing serum DHT more than 0.2 mg. Serum DHT and scalp DHT are different, and 1 mg is believed to reduce scalp DHT more effectively, contributing to better hair growth results.
community PP405 Phase 2a press release with early results
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
community Recent Study finds Laser caps are more effective than 5% minoxidil for AGA
Laser caps are found to be more effective than 5% minoxidil for treating hair loss, and when combined with minoxidil, they are even more effective. Some users report positive results with laser treatments, while others see no change; the devices are FDA approved, but opinions on their efficacy vary.
community The final nail in the coffin. PP405 is confirmed JXL069.
PP405 and JXL069 are confirmed to be the same molecule, leading to disappointment due to poor hair regrowth results. Users express skepticism about the credibility of Pelage and the effectiveness of JXL069.
Learn
8 / 801 results- Are there clinical studies showing that KY19382 can regrow hair in androgenic alopecia? No clinical studies have proven KY19382 regrows hair in androgenic alopecia.
- What do clinical trials say about the safety and effectiveness of SCUBE3 for hair regrowth? No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.
- Are there any clinical studies supporting follistatin as a hair loss treatment? There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.
- What types of hair loss conditions are most commonly associated with tofacitinib use in clinical settings? Published studies link tofacitinib mainly to alopecia areata and its severe variants — as an off-label drug being studied for them, not as a cause of hair loss. The evidence is mostly small, open-label or retrospective, and relapse after stopping is commonly reported.
- When will GT20029 be commercially available, and are there any clinical trials on its use? GT20029 is not approved or commercially available anywhere and remains investigational. A published 12-week Phase II study in 180 Chinese men reports hair-count gains over placebo, but no long-term or Phase III data exists, so any launch is years away at best.
learn sh-Polypeptide-7
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Beta Polypeptide
learn KY19382
learn SCUBE3
learn Follistatin
learn Tofacitinib
learn GT20029
Clinics
6 / 500 results- 29
TrichologyHair TransplantCLINICAL HAIR&HEALTHOstrava · CZ - 33
Hair TransplantHair Loss TreatmentsClinical BédardMontréal, QC · CA - 11
Hair Loss TreatmentsClinical Francisco DuarteBelo Horizonte, MG · BR - 35
Hair Loss TreatmentsClinical Hair & beautyCórdoba, CB · AR - 12Hair Loss TreatmentsClinical Aesthetic SolvayLiège · BE
- 25Hair TransplantClinical Aesthetics of TulsaTulsa, OK · US
Experts
— no results